Session Information
Date: Tuesday, June 6, 2017
Session Title: Parkinson's Disease: Pathophysiology
Session Time: 1:45pm-3:15pm
Location: Exhibit Hall C
Objective: Determine a correlation between the levels of anti-synuclein alpha antibodies and IL-1β at serum and CSF of patients with PD.
Background: PD is a progressive neurodegenerative disorder with impact of immune reactions on the pathogenesis. Recent studies revealed that abnormal aggregation and accumulation of synuclein has implicated in PD development. Higher level of SNCA at plasma and lower concentration of SNCA at CSF than at healthy control were revealed at PD. IL-1β plays an important role at regulation of immune and inflammatory responses.
Methods: Serum and cerebrospinal fluids (CSF) were obtained from 31 patient with PD (M:F=0,94:1; age=63,7±10,3 SD) – main group (MG) and 8 subject (M:F=3:1; age= 64±8,2 SD) with planned minor surgical operations under peridural anesthesia (herniotomy or pelvic plastic) – control group (CG). Non-parametric methods of statistical analysis were used. Investigation was approved by local ethic committee. All subjects signed informed consent form before including in the study. Anti-synuclein alpha antibodies (SNCA) and IL-1β concentration were determined using ELISA kits (Anti-SNCA Cloud-Clone Corp., US and Vector-Best, Russia, respectively).
Results: Anti-synuclein alpha antibodies at serum were detected at all samples of MG and at 6 (75%) samples of CG. At CSF positive results were at 10 (32,3%) samples of MG and only at 1 (12,5%) sample of CG. IL-1β was detected at all samples of both groups. Median levels of anti-synuclein alpha antibodies were at MG (serum – 5,06 ng/ml [2,82; 8,82], CSF – 0,0 ng/ml [0,0; 0,61] and at CG (serum – 3,29 ng/ml [0,34; 3,84], CSF – the single result was 0,61 ng/ml). Median levels of IL-1β were at MG (serum – 2,04 pg/ml [1,65; 3,04], CSF – 2,48 pg/ml [2,09; 2,95] and at CG (serum – 2,68 pg/ml [2,1; 2,98], CSF – 2,97 pg/ml [2,42; 4,48]. Only difference for anti-synuclein alpha antibodies at serum between MG and CG was statistically significant (Mann-Whitney test, p=0,02). No correlation was found between serum levels of anti-synuclein alpha antibodies and IL-1β of MG with use of Spearman Rank Order Correlation (R=0,18, p=0,3).
Conclusions: The level of anti-synuclein alpha antibodies may be useful for the diagnose of PD. Level of anti-synuclein alpha antibodies is not connected with non specific immune and inflammatory response.
To cite this abstract in AMA style:
A. Boika, V. Ponomarev, H. Ivanchik. Anti-synuclein alpha antibodies and IL-1β at Parkinson Disease (PD). [abstract]. Mov Disord. 2017; 32 (suppl 2). https://www.mdsabstracts.org/abstract/anti-synuclein-alpha-antibodies-and-il-1%ce%b2-at-parkinson-disease-pd/. Accessed November 22, 2024.« Back to 2017 International Congress
MDS Abstracts - https://www.mdsabstracts.org/abstract/anti-synuclein-alpha-antibodies-and-il-1%ce%b2-at-parkinson-disease-pd/